Cryopreservation of CD34+ Hematopoietic Stem Cells Using Cryofit® DMSO and Its Outcomes

Semih Başcı; Hikmettullah Batgi; Sinem Namdaroğlu

Makale detayları

Cryopreservation of CD34+ Hematopoietic Stem Cells Using Cryofit® DMSO and Its Outcomes

Yazarlar:

Semih Başcı | Hikmettullah Batgi | Sinem Namdaroğlu

Yayıncı:

Hitit University

Ana Başlıklar:

Hematoloji

Dergi:

Hitit Medical Journal Vol.7 Issue 2, pp.273-279

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001351604

pISSN:

2687-4717

Anahtar kelimeler:

Özet:

 Objective: Autologous hematopoietic stem cell transplantation auto-SCT is a key treatment for hematological malignancies and immune disorders. Cryopreservation of CD34 hematopoietic stem cells HSCs ensures transplant success. Dimethyl sulfoxide DMSO is a widely used cryoprotectant but can cause infusion-related toxicities. CryoFit DMSO aims to enhance cell viability while reducing adverse effects. This study evaluates its efficacy and safety in auto-SCT. Material and Method: A single-center, retrospective study was conducted on 80 patients who underwent auto- SCT with CD34 HSCs cryopreserved using CryoFit DMSO. Mobilization was performed using granulocyte colony-stimulating factor G-CSF  chemotherapy and plerixafor when required. CD34 cells were quantified via flow cytometry before cryopreservation. Post-transplant engraftment, transfusion needs, and infusion-related side effects were assessed. Data analysis was conducted using SPSS 26.0. Results: The median patient age was 58.5 years range: 19-75 and 53.8 n43 of the cohort sample was female. Multiple myeloma was the most common diagnosis 57.5. The median collected CD34 cell count was 5.8 x 106 kg range: 3.2-14. Post-thaw viability was 98 range: 90-99.5. Neutrophil and platelet engraftment occurred at medians of 13 and 17 days, respectively. The median hospitalization duration was 24 days range: 15-60. Infusion-related adverse effects occurred in 26.3 of patients, primarily nauseavomiting 15, all manageable. Conclusion: CryoFit DMSO effectively preserves CD34 HSCs with high post-thaw viability and favorable engraftment. Mild infusion-related toxicities were observed but were transient. The results support its continued use in auto-SCT. Further multicenter studies are required to optimize cryopreservation protocols.

 Objective: Autologous hematopoietic stem cell transplantation auto-SCT is a key treatment for hematological malignancies and immune disorders. Cryopreservation of CD34 hematopoietic stem cells HSCs ensures transplant success. Dimethyl sulfoxide DMSO is a widely used cryoprotectant but can cause infusion-related toxicities. CryoFit DMSO aims to enhance cell viability while reducing adverse effects. This study evaluates its efficacy and safety in auto-SCT. Material and Method: A single-center, retrospective study was conducted on 80 patients who underwent auto- SCT with CD34 HSCs cryopreserved using CryoFit DMSO. Mobilization was performed using granulocyte colony-stimulating factor G-CSF  chemotherapy and plerixafor when required. CD34 cells were quantified via flow cytometry before cryopreservation. Post-transplant engraftment, transfusion needs, and infusion-related side effects were assessed. Data analysis was conducted using SPSS 26.0. Results: The median patient age was 58.5 years range: 19-75 and 53.8 n43 of the cohort sample was female. Multiple myeloma was the most common diagnosis 57.5. The median collected CD34 cell count was 5.8 x 106 kg range: 3.2-14. Post-thaw viability was 98 range: 90-99.5. Neutrophil and platelet engraftment occurred at medians of 13 and 17 days, respectively. The median hospitalization duration was 24 days range: 15-60. Infusion-related adverse effects occurred in 26.3 of patients, primarily nauseavomiting 15, all manageable. Conclusion: CryoFit DMSO effectively preserves CD34 HSCs with high post-thaw viability and favorable engraftment. Mild infusion-related toxicities were observed but were transient. The results support its continued use in auto-SCT. Further multicenter studies are required to optimize cryopreservation protocols.

 Objective: Autologous hematopoietic stem cell transplantation auto-SCT is a key treatment for hematological malignancies and immune disorders. Cryopreservation of CD34 hematopoietic stem cells HSCs ensures transplant success. Dimethyl sulfoxide DMSO is a widely used cryoprotectant but can cause infusion-related toxicities. CryoFit DMSO aims to enhance cell viability while reducing adverse effects. This study evaluates its efficacy and safety in auto-SCT. Material and Method: A single-center, retrospective study was conducted on 80 patients who underwent auto- SCT with CD34 HSCs cryopreserved using CryoFit DMSO. Mobilization was performed using granulocyte colony-stimulating factor G-CSF  chemotherapy and plerixafor when required. CD34 cells were quantified via flow cytometry before cryopreservation. Post-transplant engraftment, transfusion needs, and infusion-related side effects were assessed. Data analysis was conducted using SPSS 26.0. Results: The median patient age was 58.5 years range: 19-75 and 53.8 n43 of the cohort sample was female. Multiple myeloma was the most common diagnosis 57.5. The median collected CD34 cell count was 5.8 x 106 kg range: 3.2-14. Post-thaw viability was 98 range: 90-99.5. Neutrophil and platelet engraftment occurred at medians of 13 and 17 days, respectively. The median hospitalization duration was 24 days range: 15-60. Infusion-related adverse effects occurred in 26.3 of patients, primarily nauseavomiting 15, all manageable. Conclusion: CryoFit DMSO effectively preserves CD34 HSCs with high post-thaw viability and favorable engraftment. Mild infusion-related toxicities were observed but were transient. The results support its continued use in auto-SCT. Further multicenter studies are required to optimize cryopreservation protocols.

 Amaç: Otolog hematopoetik kök hücre nakli OKHN, hematolojik maligniteler ve immün bozukluklar için önemli bir tedavi yöntemidir. CD34 hematopoetik kök hücrelerin HKH kriyoprezervasyonu, nakil başarısını sağlamak için kritik bir adımdır. Dimetil sülfoksit DMSO, yaygın olarak kullanılan bir kriyoprotektandır ancak infüzyona bağlı toksisiteler oluşturabilir. CryoFit DMSO, hücre canlılığını artırmayı ve olumsuz etkileri azaltmayı amaçlamaktadır. Bu çalışma, DMSO ile kriyoprezervasyonun OKHNde etkinliğini ve güvenliğini değerlendirmektedir. Gereç ve Yöntem: Bu çalışma, tek merkezli retrospektif bir analiz olup daha önceden CryoFit DMSO ile kriyoprezervasyon yapılmış kök hücrelerden OKHN olan 80 hasta dahil edildi. Kök hücre mobilizasyonu, granülosit koloni stimüle edici faktör G-CSF  kemoterapi ve gerekli durumlarda plerixafor kullanılarak gerçekleştirilmiştir. CD34 hücreleri kriyoprezervasyondan önce akış sitometrisi ile sayıldı. Nakil sonrası kök hücre yamanması engraftment, transfüzyon ihtiyacı ve infüzyona bağlı yan etkiler değerlendirildi. Veri analizi SPSS 26.0 yazılımı ile yapıldı. Bulgular: Hastaların medyan yaşı 58.5 aralık: 19-75, ve kohortun 53,8i kadındı. En yaygın tanı multipl miyelomdu 57,5. Toplanan CD34 hücrelerin medyan miktarı 5.8 x 106kg aralık: 3.2-14 idi. Çözündürme sonrası hücre canlılığı 98 aralık: 90-99.5 olarak bulundu. Nötrofil ve trombosit engraftmanı sırasıyla medyan 13 ve 17 gün olarak izlendi. Medyan hastanede kalış süresi 24 gün aralık: 15-60 idi. Hastaların 26,3ünde infüzyona bağlı yan etkiler gözlendi, en yaygın olanı bulantıkusmaydı 15 ve tüm yan etkiler yönetilebilir düzeydeydi. Sonuç: CryoFit DMSO, CD34 HKHların çözündürme sonrası yüksek canlılık oranları ile etkin bir şekilde korunmasını sağlamıştır. Hafif infüzyona bağlı toksisiteler gözlemlenmiş ancak geçici olmuştur. Bu sonuçlar, CryoFit DMSOnun OKHNde kullanımını desteklemektedir. Kriyoprezervasyon protokollerini optimize etmek için çok merkezli ileri çalışmalar gereklidir.

Makale detayları

Cryopreservation of CD34+ Hematopoietic Stem Cells Using Cryofit® DMSO and Its Outcomes

Yazarlar:

Semih Başcı | Hikmettullah Batgi | Sinem Namdaroğlu

Yayıncı:

Hitit University

Ana Başlıklar:

Hematoloji

Dergi:

Hitit Medical Journal Vol.7 Issue 2, pp.273-279

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001351604

pISSN:

2687-4717

Cryopreservation

dimethyl sulfoxide

engraftment

hematopoietic stem cell transplantation

mobilizationDimetil sülfoksit

hematopoetik kök hücre transplantasyonu

kriyoprezervasyon

dimetil sülfoksit

mobilizasyon

engrafman

Sayı

Makale detayları

Yazarlar: Semih Başcı | Hikmettullah Batgi | Sinem Namdaroğlu

Yayıncı: Hitit University

Ana Başlıklar: Hematoloji

Dergi: Hitit Medical Journal Vol.7 Issue 2, pp.273-279

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001351604

pISSN: 2687-4717

Sayı

Yazarlar:

Semih Başcı | Hikmettullah Batgi | Sinem Namdaroğlu

Yayıncı:

Hitit University

Ana Başlıklar:

Hematoloji

Dergi:

Hitit Medical Journal Vol.7 Issue 2, pp.273-279

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001351604

pISSN:

2687-4717